Jupiter Wellness stock hits 52-week low at $0.66 By Investing.com

In a challenging market environment, Jupiter Wellness Inc’s stock has touched a 52-week low, reaching a price level of $0.66. This latest price point reflects a significant downturn from the company’s performance over the past year, with the stock experiencing a 1-year change of -9.29%. Investors are closely monitoring the stock as it navigates through market pressures, with the 52-week low serving as a critical indicator of the company’s current valuation and investor sentiment.

In other recent news, Safety Shot Inc., a wellness and dietary supplement company, announced a series of strategic partnerships and initiatives aimed at expanding its market presence. The company has formed alliances with Atlantic Beverage Distributors and Prime CSB to extend the distribution of its wellness product into the Northeastern markets of Massachusetts, Rhode Island, New York, and New Jersey. Additionally, a partnership with Capital Drugs, a pharmacy chain with 300 locations nationwide, marks a significant expansion of its retail presence across the United States.

Safety Shot Inc. successfully raised $5 million in funding from Core 4 Capital Corp, issuing 2,369,668 shares at a price of $2.11 each to support the development of its flagship product, a beverage aimed at rapid alcohol detoxification. The company also announced the launch of its formula in a new 4-ounce bottle format, expected to hit the shelves in Q3, catering to consumers with active lifestyles.

The company is actively pursuing business-to-business sales channels throughout 2024, targeting distributors, retailers, restaurants, and bars to further its market reach. Lastly, Safety Shot has announced a partnership with the Nelk Boys, a prominent entertainment group, to serve as brand ambassadors, aiming to boost product awareness. These recent developments indicate a strategic growth trajectory for Safety Shot Inc. in the wellness and dietary supplement market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.